Search

Search Constraints

You searched for: Author/Creator Decker, T.

Search Results

1. 1869 Disease characteristics of subgroup patients treated with everolimus + exemestane for <12 months, ≥12 to <18months, and ≥18 months - Results of the 3rd interim analysis of the non-interventional trial BRAWO. (September 2015)

2. 433 Decrease of pro-angiogenic monocytes predicts clinical response to anti-angiogenic treatment in patients with metastatic renal cell carcinoma (mRCC). (September 2015)

3. Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306). (October 2017)

6. Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system. (October 2020)

7. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). (January 2019)